Midcareer Development Award in Neuroaging and Geriatric Pharmacoepidemiology Research

神经衰老和老年药物流行病学研究职业中期发展奖

• 批准号: 10351611
• 负责人: Allison Willis
• 金额: $ 16.32万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10351611
• 关键词: Address; Advisory Committees; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Anti-Cholinergics; Award; Basic Science; Biological; Biometry; Caliber; Caring; Chronic; Clinical; Coupled; Data Analyses; Data Collection; Data Set; Dementia; Dementia with Lewy Bodies; Development; Discipline; Disease; Drug Exposure; Drug Interactions; Drug Prescriptions; Educational Background; Elderly; Electronic Health Record; Environment; Epidemiology; Epilepsy; Evaluation; Event; Exposure to; Funding; Geriatrics; Goals; Guidelines; Health; Health Disparities Research; Health Services; Health Services Research; Health system; Huntington Disease; Impaired cognition; Individual; Informatics; Infrastructure; Intellectual functioning disability; International; Investigation; Knowledge; Learning; Lewy Body Dementia; Link; Medical; Medicare claim; Mentors; Mentorship; Methodology; Mid-Career Clinical Scientist Award (K24); Minority; Modeling; Monitor; Motor; Multiple Sclerosis; Neighborhoods; Neurologic; Neurologic Dysfunctions; Neurologist; Neurology; Observational Study; Outcome; Parkinson Disease; Parkinson' s Dementia; Patients; Pennsylvania; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacology; Pharmacotherapy; Population; Process; Psychiatry; Public Health; Quality of Care; Reporting; Research; Research Design; Research Infrastructure; Research Methodology; Research Personnel; Research Training; Risk; Role; Safety; Sampling; System; Time; Training; Training Programs; Traumatic Brain Injury; Treatment outcome; Universities; analytic epidemiology; care delivery; care outcomes; career; chronic neurologic disease; clinical care; clinical practice; cognitive function; collaborative environment; dementia risk; design; drug development; epidemiology study; evidence base; health care disparity; health care service utilization; health disparity; health equity; health service use; high risk; improved; innovation; insight; medical specialties; mild cognitive impairment; mixed dementia; multidisciplinary; neighborhood disadvantage; nervous system disorder; next generation; novel; patient oriented; patient oriented research; programs; prospective; recruit; research and development; social factors; success; treatment adherence

Dr. Willis is a neurologist, neuroepidemiologist, and health services researcher who has established a nationally- and internationally- recognized, independently funded research program committed to patient-oriented research focused on drug effects, care process and outcome disparities, and health service use in older adults with neurological disease. She has a successful record in mentoring trainees who approach POR from multiple educational backgrounds. Proposal aims: (1) to conduct analytical epidemiology research examining the impact of prescribing practices, drug exposures, drug-drug and drug-disease interactions on clinical, patient-reported and health care utilization outcomes in older adults, particularly those with Parkinson Disease + Dementia; Dementia with Lewy Bodies (which together comprise Lewy Body Dementia, an Alzheimer’s Disease Related Dementia/ADRD), Alzheimer’s disease (AD), Mild cognitive impairment and chronic neurological disease; (2) to conduct health disparities and health services research in older adults with neurological disease, particularly those with the above ADRDs and AD, to gain actionable insights into systematic barriers to equal care; (3a) to develop new studies at the intersection of aging, neurology, and pharmacoepidemiology focused on the biological, clinical, and qualitative effects of deprescribing and safety-guided CNS drug prescribing on cognitive function and cognitive decline in individuals with the above ADRDs, AD, and MCI; (3b) to develop new studies at the intersection of aging, disparities, and health services research, focused on describing and decomposing the relative contributions of individual, neighborhood, and social factors on disparities in guideline adherent treatment initiation, escalation, and monitoring; treatment adherence and outcomes in older adults with neurological disease, including ADRDs and AD; (4) to use Dr. Willis’s research program to train and mentor new investigators in research methods that will improve health care outcomes for older adults with ADRDs, AD and chronic neurological disorders through neuroprotective prescribing, more effective and equitable care delivery. A K24 award will provide Dr. Willis with the protected time needed to develop new research focused on neuroprotective prescribing and health disparities, generate knowledge on the drivers and effects of medical care and drug therapies for neurological disorders. A K24 will also allow Dr. Willis to increase her mentoring expertise and develop a formal mentoring program for engaging young investigators drawn from neurology, epidemiology, geriatrics, psychiatry, pharmacology, informatics, and biostatistics. Dr. Willis’s mentoring program will (1) provide mentees with direct exposure to primary data collection and secondary data analysis (2) create an interdisciplinary environment where trainees from a range of specialties will learn directly from each other (3) provide mentees with individualized research and career mentoring from her. The outstanding institutional environment and the K24 Advisory Team Dr. Willis has assembled to monitor and guide her progress at the University of Pennsylvania support the success of this proposal.

Willis博士是一位神经学家，神经流行病学家和卫生服务研究员，他建立了一个国家和国际认可的独立资助的研究计划，致力于以患者为导向的研究，重点关注药物效果，护理过程和结果差异，以及老年人神经系统疾病的卫生服务使用。她有一个成功的记录，指导学员谁接近POR从多种教育背景。建议的目的：（1）进行分析流行病学研究，检查处方实践，药物暴露，药物-药物和药物-疾病相互作用对老年人，特别是帕金森病+痴呆症患者的临床，患者报告和医疗保健利用结果的影响;路易体痴呆（其一起包括路易体痴呆、阿尔茨海默病相关痴呆/ADRD）、阿尔茨海默病（AD）、轻度认知障碍和慢性神经系统疾病;（2）对患有神经系统疾病的老年人，特别是患有上述ADRD和AD的老年人进行健康差异和卫生服务研究，以获得对平等护理的系统性障碍的可操作见解;（3a）在衰老、神经学和药物流行病学的交叉点开展新的研究，重点是生物学、临床、以及停用和安全性指导的CNS药物处方对上述ADRD、AD和MCI患者认知功能和认知下降的定性影响;（3b）在老龄化、差距和卫生服务研究的交叉点上开展新的研究，重点是描述和分解个人、邻里，和社会因素对指南依从性治疗启动、升级和监测的差异;老年神经系统疾病（包括ADRD和AD）患者的治疗依从性和结局;（4）利用威利斯博士的研究项目，培训和指导新的研究人员，研究方法将通过神经保护性处方改善患有ADRD，AD和慢性神经系统疾病的老年人的医疗保健结果，更有效和公平地提供保健服务。K24奖将为Willis博士提供所需的保护时间，以开发专注于神经保护性处方和健康差异的新研究，产生关于神经系统疾病的医疗保健和药物治疗的驱动因素和影响的知识。Willis博士还将增加她的指导专业知识，并制定一个正式的指导计划，吸引来自神经学，流行病学，老年医学，精神病学，药理学，信息学和生物统计学的年轻研究人员。威利斯博士的指导计划将（1）为学员提供直接接触初级数据收集和二级数据分析（2）创造一个跨学科的环境，来自一系列专业的学员将直接相互学习（3）为学员提供个性化的研究和职业指导。杰出的机构环境和K24顾问团队威利斯博士已经组装，以监测并指导她在宾夕法尼亚大学的进步支持这一建议的成功。